Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center, Prospective, Non-comparative Clinical Trial of Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome

NCT05137496 is registered in ClinicalTrials.gov with Beijing Friendship Hospital as lead sponsor.

NCT NCT05137496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05137496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center, Prospective, Non-comparative Clinical Trial of Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome
Lead sponsor
Beijing Friendship Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
June 1, 2022
Completion date
June 1, 2024
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

macrophage activation syndrome